MedTrace Logo

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

NCT01987765 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 847

Last updated 2014-04-29

Study results available
· View outcomes & findings →

Summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

Conditions

  • Conjunctivitis, Allergic

Interventions

DRUG

Relestat Ophthalmic Solution 0.05%

Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987765 on ClinicalTrials.gov